The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Nastech Pharmaceutical Company Inc.  (NSTK) Trade Now »     Rate NSTK  -  Discuss NSTK  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
64.5%
Top:
100.0%
Rate NSTK:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

NSTK: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Bearish on NSTK ... Graphic_rating_sell NSTK
17%
INGREDIANTS FOR FAILURE AS STATED 9/2007. STILL IN TACT AND IN FACT NSTK IS IN WORSE SHAPE NOW THAN IN SEPTEMBER 2007. CORPORATE GOVERNANCE IS IN QUESTION! wHAT WILL TAKE PLACE FIRST, NEW NAME CHANGE OR A $1.00 ON THE BID?
By  JIMMY T   (-14.40%  risk: moderate)  05/15/08 Comment


Bearish on NSTK ... Graphic_rating_sell NSTK
N/A
5/11/08 WHAT DOES RESEARCH FIRMS, THEIR TARGET PRICES, JIM CRAMER, AND STAR MINE ANALYST,TAUNYA SELL, OF RAGEN MACKENZIE ALL HAVE IN COMMON WITH NSTK? ANSWER:TOUTING& PUMPING. FROM $18 TO $1.18-CHRONIC MISINFORMATION ABOUT THIS STOCK! There is no excuses for the above, with all the latest technology in todays world, their staffs, and actual statistics and companies past history to date, to be so wrong as they have been. The events in 2007 were all too evident and mislead shareholders which caused financial ruins to many.
By  jturano   (+0.00%  risk: aggressive)  05/12/08 Comment


BooYah BabyCakes, Slice & Dice the DumbAsses Graphic_rating_buy NSTK
Godathiscomputer
83%

performance here MUST be all the coffee

By  Andrew Jewell   (+28.02%  risk: aggressive)  04/16/08 3 comments


Bearish on NSTK ... Graphic_rating_sell NSTK
17%
There is no doubt that all are witnessing the Funeral of NSTK as of Feb.17th. The Book Value of $1.93 will have to be adjusted before the Year end earnings report comes out on March 5th.*New Lows are still being made showing no further support or bottoming, therefore it looks like no end in sight for stock price as it continues to deteriorate What a disaster after 24 years, not for management but for investors financially.
By  JIMMY T   (-14.40%  risk: moderate)  02/17/08 Comment


Touting stars getting picked off one by one! Graphic_rating_sell NSTK
17%
Biggest Cheerleader of all-JIM CRAMER-GONE Next Biggest Cheerleader-Robert Uhl, whose chronic upgrades and high target prices were never met-GONE Robert Uhl's former employer-Friedman,billings,Ramsey group-Dropped all coverage on NSTK-GONE Whose left, The Institutions? With hardly any Revenue, higher expenses, and no major drug approvals/ or close to getting approved, management continues to get paid and still have their options and raises. Funny but it's the Chinese New Year right now, "YEAR OF THE RAT", and life goes on for management and investors are left financially ruined. I wo...
By  JIMMY T   (-14.40%  risk: moderate)  02/10/08 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.44% 381
2 Gerald Greene 18.14 +71.24% 211
3 stockmarketfunding.com 17.66 +25.60% 55
4 akiralegrand 13.47 +14.32% 62
5 anup2104 12.13 +74.22% 40


POPULAR STOCKS
Symbol Company Name Sentiment
FNM Fannie Mae
AMZN Amazoncom Inc
GLD streetTRACKS Gold
WFC Wells Fargo & Company
IBM International Business Machines Corp
JPM JPMorgan Chase & Co

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on NSTK

Visit streetinsider.com


Discussion Wall + Add  
crsathish   (+3.80%  risk: aggressive)


More Resources

Graphic_arrow1 About Nastech Pharmaceutical Company Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch